Logo image of MEDS

TRXADE HEALTH INC (MEDS) Stock Fundamental Analysis

NASDAQ:MEDS - Nasdaq - US89846A4058 - Common Stock - Currency: USD

7.59  +0.35 (+4.83%)

After market: 7.591 +0 (+0.01%)

Fundamental Rating

3

Overall MEDS gets a fundamental rating of 3 out of 10. We evaluated MEDS against 39 industry peers in the Health Care Technology industry. The financial health of MEDS is average, but there are quite some concerns on its profitability. MEDS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MEDS has reported negative net income.
In the past year MEDS has reported a negative cash flow from operations.
In the past 5 years MEDS always reported negative net income.
MEDS had negative operating cash flow in 4 of the past 5 years.
MEDS Yearly Net Income VS EBIT VS OCF VS FCFMEDS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

The Return On Assets of MEDS (28.09%) is better than 97.44% of its industry peers.
MEDS has a better Return On Equity (35.39%) than 97.44% of its industry peers.
Industry RankSector Rank
ROA 28.09%
ROE 35.39%
ROIC N/A
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.91%
ROE(5y)-784.75%
ROIC(3y)N/A
ROIC(5y)N/A
MEDS Yearly ROA, ROE, ROICMEDS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

MEDS has a Profit Margin of 94.17%. This is amongst the best in the industry. MEDS outperforms 97.44% of its industry peers.
MEDS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 94.17%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MEDS Yearly Profit, Operating, Gross MarginsMEDS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

6

2. Health

2.1 Basic Checks

MEDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MEDS has more shares outstanding
The number of shares outstanding for MEDS has been increased compared to 5 years ago.
The debt/assets ratio for MEDS is higher compared to a year ago.
MEDS Yearly Shares OutstandingMEDS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
MEDS Yearly Total Debt VS Total AssetsMEDS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -2.40, we must say that MEDS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.40, MEDS is doing worse than 61.54% of the companies in the same industry.
There is no outstanding debt for MEDS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.4
ROIC/WACCN/A
WACC11.3%
MEDS Yearly LT Debt VS Equity VS FCFMEDS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M 6M 8M

2.3 Liquidity

A Current Ratio of 4.18 indicates that MEDS has no problem at all paying its short term obligations.
MEDS has a better Current ratio (4.18) than 74.36% of its industry peers.
MEDS has a Quick Ratio of 4.18. This indicates that MEDS is financially healthy and has no problem in meeting its short term obligations.
MEDS has a Quick ratio of 4.18. This is in the better half of the industry: MEDS outperforms 79.49% of its industry peers.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 4.18
MEDS Yearly Current Assets VS Current LiabilitesMEDS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

MEDS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.73%, which is quite impressive.
Looking at the last year, MEDS shows a very negative growth in Revenue. The Revenue has decreased by -53.03% in the last year.
Measured over the past years, MEDS shows a quite strong growth in Revenue. The Revenue has been growing by 16.65% on average per year.
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MEDS Yearly Revenue VS EstimatesMEDS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
MEDS Yearly EPS VS EstimatesMEDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MEDS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MEDS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MEDS Price Earnings VS Forward Price EarningsMEDS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEDS Per share dataMEDS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 125.16%, MEDS is a good candidate for dividend investing.
MEDS's Dividend Yield is rather good when compared to the industry average which is at 38.42. MEDS pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.27, MEDS pays a better dividend.
Industry RankSector Rank
Dividend Yield 125.16%

5.2 History

MEDS is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MEDS Yearly Dividends per shareMEDS Yearly Dividends per shareYearly Dividends per share 2024 2 4 6 8

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
MEDS Yearly Income VS Free CF VS DividendMEDS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

More info and screens

TRXADE HEALTH INC

NASDAQ:MEDS (9/20/2024, 8:07:08 PM)

After market: 7.591 +0 (+0.01%)

7.59

+0.35 (+4.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)07-22 2024-07-22/amc
Earnings (Next)N/A N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners309.26%
Ins Owner Change0%
Market Cap11.08M
Analysts82.86
Price Target6.89 (-9.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 125.16%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-99.59%
Min Revenue beat(2)-100%
Max Revenue beat(2)-99.18%
Revenue beat(4)0
Avg Revenue beat(4)-53.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)-1.65%
Revenue beat(8)1
Avg Revenue beat(8)-31.56%
Revenue beat(12)5
Avg Revenue beat(12)-13.38%
Revenue beat(16)7
Avg Revenue beat(16)-4.94%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-6.71
FCFYN/A
OCF(TTM)-5.1
OCFYN/A
SpS3.03
BVpS8.07
TBVpS8.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 28.09%
ROE 35.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.17%
GM N/A
FCFM N/A
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.91%
ROE(5y)-784.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 4.18
Altman-Z -2.4
F-Score4
WACC11.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-909.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.13%
OCF growth 3YN/A
OCF growth 5YN/A